Skip to content

Clinical study to detect the presence of silicone oil released by syringes used for intraocular injection

Detection of silicone oil from the syringe in the vitreous of patients undergoing intravitreal injection: a double-blind randomized clinical trial

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
REBEC
Registry ID
RBR-10tn82jt
Enrollment
Unknown
Registered
2022-10-18
Start date
2021-11-01
Completion date
Unknown
Last updated
2025-10-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetic retinopathy

Interventions

This is a double-blind, randomized controlled clinical trial. Experimental group: 50 eyes of patients with diabetic retinopathy will receive an intravitreal injection of bevacizumab with a syringe wit

Sponsors

Hospital de Olhos de Sergipe
Lead Sponsor
SJJ Solutions
Collaborator

Eligibility

Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: Over 18 years of age; both sexes; diabetic retinopathy, with indication for intravitreal injection of bevacizumab; clear ocular media and adequate pupillary dilation in both eyes to allow for all imaging procedures; visual acuity between 20/25 and 20/400; provide written consent; availability to come for exam 3 days after first injection and monthly for new exams and injection for 6 months

Exclusion criteria

Exclusion criteria: Severe glaucoma; age-related macular degeneration or retinal dystrophy; previous or current history of uveitis; previous vitreoretinal surgery; systemic contraindication to antiangiogenic therapy; presence of intraocular inflammation; any intraocular surgery in the previous 3 months; any eye infection; pregnancy or breastfeeding; any of the following conditions: severe heart disease, significant peripheral vascular disease; stroke in the last 6 months

Design outcomes

Primary

MeasureTime frame
Silicone oil is expected to be found in the vitreous of patients treated with the oil-free syringe in 5 to 10% of eyes while 15 to 20% in those treated with the siliconized syringe, as assessed by slit lamp examination. Data will be collected monthly after each injection, until the 6th injection is completed.

Secondary

MeasureTime frame
Evaluate whether there will be a difference in anterior chamber reaction (inflammation) with the use of the oil-free syringe compared with the siliconized syringe, assessed by slit lamp examination. Data will be collected only on the day of the first injection and 72 hours later.

Countries

Brazil

Contacts

Public ContactGustavo Melo

Hospital de Olhos de Sergipe

gustavobmelo80@gmail.com+557932120800

Outcome results

None listed

Source: REBEC (via WHO ICTRP)